Dr Catherine Tang
BSc(Med)Hons, MBBS(Hons I), FRACP, FRCPA, Haematologist
I am a dedicated advocate for my patients, endeavouring to combine the best evidence-based care with perspective, understanding and kindness.
English, Cantonese, Mandarin
Special clinical interest in lymphoma, myeloma, lymphoproliferative disorders, thrombosis and medical education.
Catherine is a dual-trained Clinical and Laboratory Haematologist with special interest in Lymphoma and Myeloma. Graduating with first-class honours from UNSW, she completed her Advanced Haematology training at Royal North Shore and Gosford Hospitals. Catherine then undertook a Clinical Fellowship in Lymphoma, Myeloma and Transplant at the renowned Princess Margaret Cancer Centre in Toronto, Canada, working with world leaders in the treatment of lymphoproliferative disorders. During this time, she was also awarded several International Young Investigator Awards for her research in malignant haematology.
Catherine was then appointed as a Consultant Haematologist, Clinical Lead in Hodgkin Lymphoma and Thrombosis in Wellington Hospital, New Zealand. This involved an active research portfolio including as a co-investigator in CAR-T cell trials. Catherine is also passionate about medical education as a Senior Clinical Lecturer at the University of Otago, Wellington.
Catherine takes pride in delivering thorough and empathetic care to her patients. She brings a considered, straight forward approach to ensure patients are supported through each step of their diagnosis and treatment.
- American Society of Haematology Clinical Training Research Institute Grant
- Canadian Lymphoproliferative Disorders Young Investigator Award
- European Haematology Association Young Investigator Travel Grant
- University of Sydney School of Public Health Clinical Epidemiology Scholarship
- Lymphoma clinical trials
- Cellular therapies
- Australasian Lymphoma and Leukaemia Research Group (ALLG) - Supportive Care and Lymphoma Working Party member.
- Haematology Society of Australia & New Zealand (HSANZ) member
- American Society of Haematology (ASH) member
- Australasian Lymphoma Alliance (ALA) member
- NSW eVIQ Haematology and BMT reference committee member
- Tang, C., Espin-Garcia, O, Prica, A., Kukreti, V., Kridel, R., Keating, A., Patriquin, C., Kuruvilla, J & Crump, M. Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. Leukemia & Lymphoma. 2020 61(9):2153-2160
- Tang, C., Rabbolini, DJ., Morel-Kopp, MC., Connor DE., Cripsin, P., Ward CM & Stevenson, WS. Clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy. Research and Practice in Thrombosis and Haemostasis 2020 4(1):106-110
- Tang, C. & Kuruvilla, J. Optimal management of mantle cell lymphoma in the primary setting. Expert Reviews in Hematology. 2019. 12(9):715-721